Experimental drug `nothing short of miraculous` for father of 4 with super-rare brain tumor
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This is the drug that we recently gave a million dollar grant to help support and speed up it's development! The mutation (H3K27 M) is very common in DIPG, and common in midline and thalmic malignant gliomas, more so in younger GBM patients. This experimental drug is in clinical trials. Check your pathology report to see if you have this mutation. If you do, contact us and we can help you find a trial. (It is so common in DIPG that no biopsy is needed to get into the trials for that tumor type - it is assumed they all have this)
Posted on: 09/20/2018
Click HERE to return to brain tumor news headlines
|